GHIT Fund’s $862K Portable Ebola Diagnostic Targets Bundibugyo Virus Outbreak

On July 23, 2026, the Global Health Innovative Technology (GHIT) Fund announced an investment of JPY 140 million (approximately USD 862,000) to develop a portable rapid diagnostic system for Ebola disease caused by the Bundibugyo virus (BDBV). The project is a joint effort among Osaka Metropolitan University, K.K. DNAFORM, and the Democratic Republic of the Congo's National Institute for Biomedical Research (INRB).

This investment comes during a major outbreak of Bundibugyo virus disease in the DRC and Uganda, for which there is no licensed vaccine or specific treatment. The project is a direct response to the WHO's declaration of a Public Health Emergency of International Concern (PHEIC) and aligns with the global 100-Day Mission (100DM) for pandemic preparedness.

Project Partners

• Osaka Metropolitan University – Prof. Yasutoshi Kido (Virology, Graduate School of Medicine) leads the research.
• K.K. DNAFORM – A Japanese biotechnology company providing the core diagnostic platform.
• INRB (Institut National de Recherche Biomédicale) – The DRC's national biomedical research institute, enabling in-country clinical evaluation.

Technology Platform

The system uses SmartAmp isothermal PCR technology with Eprobe detection, a platform developed by K.K. DNAFORM. It is a point-of-care testing (POCT) platform designed to be portable and deployable in field conditions where infrastructure is limited. The platform, called GenPad, is battery-powered (7.2VDC, 21.6Wh), weighs 460g, and can perform up to 8 tests per charge, delivering results from a blood sample in approximately 30 minutes. The initial milestones cover prototype development, performance validation, and preparation for clinical evaluation in the DRC.

Outbreak Context: Bundibugyo Virus in the DRC and Uganda

PHEIC Declaration

On May 16, 2026, the WHO Director-General determined that the Bundibugyo virus disease outbreak constitutes a Public Health Emergency of International Concern (PHEIC) under the International Health Regulations (2005). The outbreak was first declared by the DRC and Ugandan ministries of health on May 15, 2026.

Case and Death Counts (mid-July 2026)

Location	Confirmed Cases	Confirmed Deaths	CFR (approx.)	Data as of
DRC	1,759	600	~34%	July 7 (reported July 8)
Uganda	20 confirmed + 1 probable	2 confirmed + 1 probable	~9–14%	July 2
Total (DRC + Uganda)	~1,779 confirmed	~602 confirmed deaths	~34%	July 7–8, 2026

Note: The ECDC report of July 21, 2026 (citing DRC data through July 7) also notes 750+ patients hospitalized in isolation and 285 recovered in the DRC. The Wikipedia summary for the 2026 epidemic reports 1,780 confirmed cases, 304 suspected cases, 303 recovered, and 602 deaths as of July 7, 2026, with a fatality rate of 33.8%.

No Licensed Vaccine or Treatment for Bundibugyo Strain

The WHO explicitly states that the Bundibugyo species (BDBV) is "one for which there is no vaccine or specific treatment", though work is ongoing to test promising candidates. Existing Ebola vaccines (e.g., rVSV-ZEBOV) are effective against Zaire ebolavirus but not cross-protective for Bundibugyo virus.

Alignment with the 100-Day Mission

The 100-Day Mission (100DM) is a global initiative, endorsed by the G7 and G20, that aims to make safe, effective, and affordable diagnostics, therapeutics, and vaccines available within 100 days of a pandemic threat being identified (defined as when WHO declares a PHEIC). Rapid point-of-care diagnostics are explicitly listed as the first of three required interventions under the mission.

This GHIT Fund project aligns with the 100-Day Mission in several key ways:

• Direct trigger: The WHO PHEIC declaration on May 16, 2026, was the 100-Day Mission's defined starting clock. The GHIT Fund launched its emergency RFP just six days later on May 22, 2026.
• Diagnostics as pillar: Rapid point-of-care diagnostics are the first priority intervention within the 100-Day Mission framework.
• Closing a known gap: As of June 2026, the International Pandemic Preparedness Secretariat noted that no approved diagnostics, therapeutics, or vaccines existed for this species — the 100-Day Mission directly calls for filling exactly such gaps.
• Portable, field-ready design: The SmartAmp isothermal platform (GenPad) is designed for near-point-of-care use in outbreak settings, matching the mission's requirement for deployable diagnostic capacity.

In short, this investment is a concrete, rapid-response R&D effort triggered by a PHEIC, targeting a pathogen with no existing countermeasures, using a platform designed for field deployment — directly executing the diagnostic pillar of the 100-Day Mission.